|
KMID : 0923620140140050237
|
|
Immune Network
2014 Volume.14 No. 5 p.237 ~ p.240
|
|
|
Contrasting Roles of Different Endoglin Forms in Atherosclerosis
|
|
Jang Young-Saeng
Choi In-Hong
|
|
|
Abstract
|
|
|
|
Endoglin (also known as CD105 or TGF-β type III receptor) is a co-receptor involved in TGF-β signaling. In athero-sclerosis, TGF-β signaling is crucial in regulating disease progression owing to its anti-inflammatory effects as well as its inhibitory effects on smooth muscle cell proliferation and migration. Endoglin is a regulator of TGF-β signaling, but its role in atherosclerosis has yet to be defined. This review fo-cuses on the roles of the various forms of endoglin in atherosclerosis. The expression of the two isoforms of endo-glin (long-form and short-form) is increased in athero-sclerotic lesions, and the expression of the soluble forms of endoglin is upregulated in sera of patients with hyper-cholesterolemia and atherosclerosis. Interestingly, long-form endoglin shows an atheroprotective effect via the induction of eNOS expression, while short-form and soluble endoglin enhance atherogenesis by inhibiting eNOS expression and TGF-β signaling. This review summarizes evidence suggest-ing that the different forms of endoglin have distinct roles in atherosclerosis.
|
|
|
KEYWORD
|
|
|
Endoglin, Atherosclerosis, TGF-β, Smad
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|